You're asking about a rather specific compound, **1-amino-5-(4-morpholinyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carboxylic acid ethyl ester**. Let's break down its structure and potential importance in research.
**Structure and Properties:**
* **1-amino-5-(4-morpholinyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carboxylic acid ethyl ester:** This is a complex organic molecule with a fused ring system. Let's break it down piece by piece:
* **Thieno[2,3-c]isoquinoline:** This is a bicyclic system where a thiophene ring (sulfur-containing ring) is fused to an isoquinoline ring (nitrogen-containing ring).
* **6,7,8,9-tetrahydro:** This indicates that the isoquinoline ring has four hydrogen atoms attached to the carbon atoms at positions 6, 7, 8, and 9, meaning it's not fully aromatic.
* **1-amino:** This indicates that an amino group (NH2) is attached to the isoquinoline ring at position 1.
* **5-(4-morpholinyl):** This means a morpholine ring (containing a nitrogen and an oxygen) is attached to the isoquinoline ring at position 5.
* **2-carboxylic acid ethyl ester:** This refers to an ethyl ester group (-COOC2H5) attached to the carbon at position 2 on the isoquinoline ring.
**Potential Research Importance:**
The detailed information about this specific compound's research importance is not readily available in general resources. However, we can make some educated guesses based on its structural features:
* **Potential Biological Activity:**
* **Heterocyclic Structure:** The thieno[2,3-c]isoquinoline core, along with the morpholine ring, is known to appear in molecules with potential biological activity. This structure is often found in compounds with drug-like properties.
* **Amino Group:** The amino group can potentially interact with biological targets, potentially influencing enzyme activity or receptor binding.
* **Carboxylic Acid Ethyl Ester:** The ester group can be a site for chemical modification, allowing for the development of analogues with different properties.
* **Drug Discovery:** The compound could be a potential lead compound for drug discovery. Its structure suggests it could exhibit biological activity against certain diseases or conditions.
**To find out more about this specific compound's research importance, you would need to:**
1. **Search Scientific Databases:** Use databases like PubMed, Scopus, Web of Science, or Google Scholar with specific keywords like thieno[2,3-c]isoquinoline, morpholine, amino, carboxylic acid ethyl ester, and the specific compound name.
2. **Consult Chemical Databases:** Databases like ChemSpider or PubChem might have information on this compound's synthesis, properties, and potential biological activity.
3. **Look for Published Research:** Look for research papers or patents mentioning this specific compound or related compounds.
Remember, without specific information about the compound's synthesis, biological testing, or applications, it's hard to say definitively why it would be important.
ID Source | ID |
---|---|
PubMed CID | 658121 |
CHEMBL ID | 1336329 |
CHEBI ID | 108450 |
Synonym |
---|
ethyl 1-amino-5-morpholin-4-yl-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carboxylate |
smr000034349 |
MLS000038157 |
OPREA1_209160 |
OPREA1_729633 |
ethyl 1-amino-5-(morpholin-4-yl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carboxylate |
STK093843 |
CHEBI:108450 |
MLS002581674 |
AKOS000279732 |
CCG-18838 |
HMS2337K18 |
CHEMBL1336329 |
Q27187298 |
1-amino-5-(4-morpholinyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carboxylic acid ethyl ester |
SR-01000470378-1 |
sr-01000470378 |
ethyl 1-amino-5-(morpholin-4-yl)-6h,7h,8h,9h-thieno[2,3-c]isoquinoline-2-carboxylate |
Class | Description |
---|---|
thienopyridine | Any organic heterobicyclic compound whose skeleton results from the formal ortho-fusion of any bond of a pyridine with any bond of a thiophene. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 3.1623 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 3.1623 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 7.9433 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 22.5358 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
ClpP | Bacillus subtilis | Potency | 31.6228 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
GLS protein | Homo sapiens (human) | Potency | 3.9811 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 12.9953 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
67.9K protein | Vaccinia virus | Potency | 14.1254 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |